Free Trial

Dr. Reddy's Laboratories (RDY) Competitors

Dr. Reddy's Laboratories logo
$14.64 -0.12 (-0.78%)
Closing price 03:59 PM Eastern
Extended Trading
$14.68 +0.04 (+0.27%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RDY vs. TAK, ARGX, ONC, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, and MRNA

Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

Dr. Reddy's Laboratories vs. Its Competitors

Takeda Pharmaceutical (NYSE:TAK) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.09B1.57$712.33M$0.2267.39
Dr. Reddy's Laboratories$3.81B3.21$663M$0.6622.19

Takeda Pharmaceutical has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Dr. Reddy's Laboratories has a consensus price target of $16.95, suggesting a potential upside of 15.74%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dr. Reddy's Laboratories
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 1 mentions for Dr. Reddy's Laboratories. Takeda Pharmaceutical's average media sentiment score of 1.67 beat Dr. Reddy's Laboratories' score of 1.67 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Dr. Reddy's Laboratories
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 17.38% compared to Takeda Pharmaceutical's net margin of 2.36%. Dr. Reddy's Laboratories' return on equity of 17.98% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical2.36% 10.64% 5.14%
Dr. Reddy's Laboratories 17.38%17.98%12.24%

Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.7%. Dr. Reddy's Laboratories pays an annual dividend of $0.08 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend.

Summary

Dr. Reddy's Laboratories beats Takeda Pharmaceutical on 11 of the 18 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDY vs. The Competition

MetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE Exchange
Market Cap$12.32B$3.91B$5.56B$20.59B
Dividend Yield0.55%1.17%5.25%3.73%
P/E Ratio22.196.6827.1528.00
Price / Sales3.2111.74441.1843.17
Price / Cash14.296.5037.5022.41
Price / Book3.102.788.084.61
Net Income$663M-$109.62M$3.16B$982.91M
7 Day Performance-2.88%10.08%3.77%3.26%
1 Month Performance-7.83%14.06%3.90%4.37%
1 Year Performance-6.39%30.06%34.22%14.95%

Dr. Reddy's Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RDY
Dr. Reddy's Laboratories
2.8222 of 5 stars
$14.65
-0.8%
$16.95
+15.7%
-5.1%$12.32B$3.81B22.1927,811Positive News
TAK
Takeda Pharmaceutical
2.4886 of 5 stars
$15.07
-1.8%
N/A+15.2%$48.81B$30.09B9.7147,455
ARGX
argenex
4.4406 of 5 stars
$546.04
+0.5%
$728.06
+33.3%
+21.3%$33.18B$2.25B33.691,599Analyst Upgrade
ONC
BeOne Medicines
3.36 of 5 stars
$240.99
-1.8%
$320.67
+33.1%
N/A$26.91B$3.81B0.0011,000
BNTX
BioNTech
1.7469 of 5 stars
$110.05
+0.0%
$137.86
+25.3%
+38.8%$26.44B$2.98B0.006,772News Coverage
Analyst Forecast
TEVA
Teva Pharmaceutical Industries
4.121 of 5 stars
$16.84
-1.0%
$24.13
+43.3%
+5.8%$19.51B$16.54B6.9736,830Options Volume
INSM
Insmed
4.6106 of 5 stars
$96.95
-0.9%
$106.80
+10.2%
+37.3%$18.55B$363.71M-16.291,271Analyst Forecast
Insider Trade
SMMT
Summit Therapeutics
2.344 of 5 stars
$22.61
-7.9%
$34.67
+53.3%
+215.6%$18.23B$700K0.00110
ITCI
Intra-Cellular Therapies
0.772 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
4.1654 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-15.8%$13.02B$3.12B14.602,682News Coverage
Positive News
Analyst Forecast
MRNA
Moderna
4.5657 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-71.7%$11.79B$3.24B0.005,800

Related Companies and Tools


This page (NYSE:RDY) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners